Global Health and Lincoln Park team up
This article was originally published in The Tan Sheet
Executive Summary
Specialty pharmaceutical firm Global Health Ventures signs an equity purchase agreement with Lincoln Park Capital Fund for up to $20 million, the Canadian maker of sublingually delivered lifestyle products said May 28. Global Health says it has the right to sell shares of common stock to the Chicago-based institutional investor over a 30-month period in amounts between $100,000 and $1 million, and up to the $20 million limit depending on conditions of the agreement. Global Health says the finance proceeds will help it develop the male enhancement drug X-Excite and other drugs, license new products and acquire other companies
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.